Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results